Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Our aim was to evaluate the effects of vitamin D supplementation in patients with chronic liver disease by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Source: Article title.

Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Systematic review · Nutrition Reviews · 2025

Original publication title

Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Petrana Martinekova; Mahmoud Obeidat; Mihaela Topala; Szilárd Váncsa; Dániel Sándor Veres; Ádám Zolcsák; Miheller Pál; László Földvári-Nagy; Peter Banovcin; Bálint Erőss; Péter Hegyi; Krisztina Hagymasi

© The Author(s) 2025. Published by Oxford University Press on behalf of the International Life Sciences Institute.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our results showed significantly reduced ALT, AST, GGT, triglycerides, insulin, and HOMA-IR in the vitamin D: supplemented group; however, the effect was modest. In addition, there were no differences in survival, CAP, or LSM. Further RCTs with adequate power are warranted to clarify the results.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Our aim was to evaluate the effects of vitamin D supplementation in patients with chronic liver disease by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).

Source: Objective

Abstract: Context

Vitamin D deficiency is highly prevalent in chronic liver disease. Although international societies recommend vitamin D supplementation in cases of proven deficiency, the impact of vitamin D on chronic liver disease remains uncertain.

Source: Context

Abstract: Data Sources

We systematically searched PubMed, EMBASE and the Cochrane Library on July 2, 2024.

Source: Data Sources

Abstract: Data Extraction

Our primary outcomes involved survival, controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and effects on changes in liver enzymes. Secondary outcomes included lipid profile and homeostasis model assessment of insulin resistance (HOMA-IR), among others. The pooled risk ratio (RR), mean difference (MD), and corresponding 95% CIs were calculated using the random-effects model.

Source: Data Extraction

Abstract: Data Analysis

Forty-six RCTs were included, comprising 4084 patients. When we compared the vitamin D group with the control, the RR for overall survival was 1.14 (95% CI, 0.85-1.54; 4 RCTs) at 6 months and 0.99 (95% CI, 0.83-1.17; 4 RCTs) at the 12-month follow-up. Vitamin D supplementation did not result in a lower CAP (MD, −23.50 dB/m; 95% CI, −81.72 to 34.72; 3 RCTs) and LSM (MD, −0.65 kPa; 95% CI, −1.98 to 0.68; 3 RCTs). A significant reduction in HOMA-IR was observed in the vitamin D group (MD, −0.31; 95% CI, −0.62 to −0.01; 15 RCTs).

Alanine aminotransferase (ALT) (MD, −4.98 IU/L; 95% CI, −8.28 to −1.68; 24 RCTs), aspartate aminotransferase (AST) (MD, −3.33 IU/L; 95% CI, −6.25 to −0.40; 23 RCTs), gamma-glutamyl transferase (GGT) (MD, −5.14 IU/L; −6.40; −3.88; 11 RCTs), triglycerides (MD, −7.59 mg/dL; 95% CI, −15.09 to −0.81), and insulin (MD −0.79 μIU/L; 95% CI, −1.36 to −0.21) were significantly reduced in the patients with vitamin D supplementation.

Source: Data Analysis

Abstract: Systematic Review Registration

PROSPERO registration No. CRD42022370312

Source: Systematic Review Registration

Abstract: Conclusion

Our results showed significantly reduced ALT, AST, GGT, triglycerides, insulin, and HOMA-IR in the vitamin D: supplemented group; however, the effect was modest. In addition, there were no differences in survival, CAP, or LSM. Further RCTs with adequate power are warranted to clarify the results.

Source: Conclusion
Authors’ abstract

Abstract

Context

Vitamin D deficiency is highly prevalent in chronic liver disease. Although international societies recommend vitamin D supplementation in cases of proven deficiency, the impact of vitamin D on chronic liver disease remains uncertain.

Objective

Our aim was to evaluate the effects of vitamin D supplementation in patients with chronic liver disease by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).

Data Sources

We systematically searched PubMed, EMBASE and the Cochrane Library on July 2, 2024.

Data Extraction

Our primary outcomes involved survival, controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and effects on changes in liver enzymes. Secondary outcomes included lipid profile and homeostasis model assessment of insulin resistance (HOMA-IR), among others. The pooled risk ratio (RR), mean difference (MD), and corresponding 95% CIs were calculated using the random-effects model.

Data Analysis

Forty-six RCTs were included, comprising 4084 patients. When we compared the vitamin D group with the control, the RR for overall survival was 1.14 (95% CI, 0.85-1.54; 4 RCTs) at 6 months and 0.99 (95% CI, 0.83-1.17; 4 RCTs) at the 12-month follow-up. Vitamin D supplementation did not result in a lower CAP (MD, −23.50 dB/m; 95% CI, −81.72 to 34.72; 3 RCTs) and LSM (MD, −0.65 kPa; 95% CI, −1.98 to 0.68; 3 RCTs). A significant reduction in HOMA-IR was observed in the vitamin D group (MD, −0.31; 95% CI, −0.62 to −0.01; 15 RCTs).

Alanine aminotransferase (ALT) (MD, −4.98 IU/L; 95% CI, −8.28 to −1.68; 24 RCTs), aspartate aminotransferase (AST) (MD, −3.33 IU/L; 95% CI, −6.25 to −0.40; 23 RCTs), gamma-glutamyl transferase (GGT) (MD, −5.14 IU/L; −6.40; −3.88; 11 RCTs), triglycerides (MD, −7.59 mg/dL; 95% CI, −15.09 to −0.81), and insulin (MD −0.79 μIU/L; 95% CI, −1.36 to −0.21) were significantly reduced in the patients with vitamin D supplementation.

Conclusion

Our results showed significantly reduced ALT, AST, GGT, triglycerides, insulin, and HOMA-IR in the vitamin D: supplemented group; however, the effect was modest. In addition, there were no differences in survival, CAP, or LSM. Further RCTs with adequate power are warranted to clarify the results.

Systematic Review Registration

PROSPERO registration No. CRD42022370312

Publication and source details

Original title: Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Petrana Martinekova; Mahmoud Obeidat; Mihaela Topala; Szilárd Váncsa; Dániel Sándor Veres; Ádám Zolcsák; Miheller Pál; László Földvári-Nagy; Peter Banovcin; Bálint Erőss; Péter Hegyi; Krisztina Hagymasi

Nutrition Reviews · 2025

Corresponding Author: Krisztina Hagymasi, Department of Surgery, Transplantation, and Gastroenterology; Semmelweis University, H-1082 Budapest, Üllői út 78, Hungary (hagymasi.krisztina@semmelweis.hu).© The Author(s) 2025. Published by Oxford University Press on behalf of the International Life Sciences Institute.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:54:16.950174+00:00

DOI: 10.1093/nutrit/nuaf117 · PMC12512233